NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory Biomarker Correlatives
Robert L. Ferris(University of Pittsburgh), Julie E. Bauman(George Washington University), R. Jordan, Quynh‐Thu Le(Stanford University), A. Kulkarni(University of Pittsburgh), Gabriel Sica(Emory University), P. Torres-Saavedra(American College of Radiology), Minh Phan(University of Oklahoma Health Sciences Center), Farzan Siddiqui, Brian R. Isett(UPMC Hillman Cancer Center), Pawan Upadhyay(University of Pittsburgh), A. Chakravati(The Ohio State University), Ravindra Uppaluri(Brigham and Women's Hospital), J. Harris(American College of Radiology), S. Jujjavarapu(OSF HealthCare), J.L. Geiger(Cleveland Clinic), Jie Chen(Nantong University), Fei Tu(Key Laboratory of Guangdong Province), Min Yao(University Hospitals of Cleveland), L. Vujanovic(University of Pittsburgh)
International Journal of Radiation Oncology*Biology*Physics
March 14, 2024
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
|Proceedings of the National Academy of Sciences|2017|899